David P. Walling, PhD

  • 5Articles
  • 56.2KReads
  • 2014–2025Active
  • 47Collaborators
  • 106Citations

About

David P. Walling, PhD, is affiliated with the Collaborative Neuroscience Network Garden Grove in California. His publications from 2014 to 2025 focus on schizophrenia, schizoaffective disorders, and major depressive disorder. His research includes clinical trials evaluating novel treatments such as NR2B negative allosteric modulators, extended-release risperidone formulations, transdermal asenapine systems, and long-acting injectable antipsychotics. Walling frequently collaborates with co-authors including Alexandra S. Park and Amy Claxton.

Publications

JCP
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
Original Research

Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study

August 6, 2025

Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
, , , et al
JCP
Original Research

Response to Subcutaneous Injectable Monthly Risperidone (RBP-7000): PANSS Item-Level Analysis

September 21, 2021

Phase 3 study data on the efficacy of RBP-7000 for schizophrenia were examined to see if dose-response relationships exist for different items of the Positive and Negative Syndrome Scale.
, , , et al
JCP
Original Research

Asenapine Transdermal System for Schizophrenia

December 15, 2020

Transdermal asenapine administration may address unmet needs in patients with schizophrenia, including improved adherence. This phase 3 study assessed efficacy and safety of HP-3070, an asenapine transdermal system (patch),...
, , , et al
JCP
Original Research

Aripiprazole Lauroxil to Treat Schizophrenia

May 19, 2020

Read a study examining the efficacy and tolerability of the long-acting injectable (LAI) aripiprazole lauroxil from inpatient into follow-up outpatient care.
, , , et al
JCP
Original Research

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

December 5, 2014

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe